Royal Bank of Canada
PHAS

Royal Bank of Canada’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Royal Bank of Canada’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,185
Closed – – 8161
2022
Q3 		$0 Buy
2,185
+185
+9% +$189 ﹤0.01% 8192
2022
Q2 		$1K Hold
2,000
– – ﹤0.01% 7291
2022
Q1 		$3K Hold
2,000
– – ﹤0.01% 7433
2021
Q4 		$5K Hold
2,000
– – ﹤0.01% 7251
2021
Q3 		$6K Sell
2,000
-956
-32% -$3.19K ﹤0.01% 7109
2021
Q2 		$11K Sell
2,956
-479
-14% -$1.59K ﹤0.01% 6855
2021
Q1 		$12K Buy
3,435
+211
+7% +$856 ﹤0.01% 6740
2020
Q4 		$11K Buy
3,224
+1,201
+59% +$4.3K ﹤0.01% 6350
2020
Q3 		$7K Sell
2,023
-108
-5% -$435 ﹤0.01% 6066
2020
Q2 		$10K Buy
+2,131
New +$9.44K ﹤0.01% 5847
2020
Q1 		– Sell
-2,921
Closed -$18K – 7176
2019
Q4 		$18K Buy
+2,921
New +$12K ﹤0.01% 5915
2019
Q3 		– Sell
-7
Closed – – 7306
2019
Q2 		$0 Buy
+7
New +$86 ﹤0.01% 7324

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada's PHAS Position: Q4 2022 in Review

Royal Bank of Canada sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 2,185 shares.

Royal Bank of Canada first reported a position in PHAS in Q2 2019 and held it in 12 quarters. The position peaked at $18K in Q4 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Royal Bank of Canada reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 2,185 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • Royal Bank of Canada first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Royal Bank of Canada's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $18K in Q4 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.